Introduction:Clostridium difficile infection is a major economic and clinical burden, due to its high frequency of recurrence. Currently recommended treatments are not efficient for prevention...
Background: Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy.
Merck announced that the two pivotal Phase III clinical studies for bezlotoxumab, its investigational antitoxin for prevention of Clostridium difficile...
The FDA has accepted for review the Biologics License Application (BLA) for MK 6072 (bezlotoxumab), from Merck, an investigational antitoxin...
The FDA's Antimicrobial Drugs Advisory Committee voted 10 to 5, with 1 abstention, to recommend Zinplava ( bezlotoxumab injection) from...
ZINPLAVA is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI (see sections 4.2, 4.4 and 5.1).
This updated guideline provides a current review of the literature on interventions to control CDI in adult populations in acute healthcare settings and derives specific infection control recommendations.
Ferring Pharmaceuticals announced the FDA approved Rebyota (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
Seres Therapeutics, Inc. and Nestlé Health Science announced the FDA approval of Vowst (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI)